---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-24-000023"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:37:46.035283+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moderna Q1 revenue $167M, net loss $1.2B; reaffirms FY 2024 sales ~$4B

## Summary
- GAAP net loss of $1.2B and diluted EPS of $(3.07) vs. $0.19 EPS a year ago.
- Spikevax product sales fell 91% YoY to $167M; $100M U.S., $67M international.
- Reaffirms 2024 product sales ~$4B; expects ~$0.3B net sales in H1 2024.
- Cash and investments $12.2B at March 31, down from $13.3B at year-end 2023.
- RSV vaccine launch targeted for fall 2024; flu vaccine filing expected in 2024.

## SEC filing metadata
- accession: 0001682852-24-000023
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000023/0001682852-24-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000023/mrna-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-24-000023
- JSON: https://secwatch.observer/filing/0001682852-24-000023.json
- Plain text: https://secwatch.observer/filing/0001682852-24-000023.txt

## Key facts
- Earnings Releases
  Moderna, Inc. reported the first quarter ended March 31, 2024 results: revenue $167 million, net income GAAP net loss of $1.2 billion, EPS GAAP diluted EPS of $(3.07). Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $167 million
  - Net income: GAAP net loss of $1.2 billion
  - EPS: GAAP diluted EPS of $(3.07)
  - Guidance: reaffirmed
  - Result: reported results
  source text: Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Reports first quarter revenues of $167 million , GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000023/0001682852-24-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.